Tuberculosis Management: Returning to Pre-Pandemic Priorities

Article Type
Article
Changed
Tue, 10/29/2024 - 12:24
Display Headline
Tuberculosis Management: Returning to Pre-Pandemic Priorities
Author(s)
Patricio Escalante, MD, MSc, FCCP, and Paige K. Marty, MD

Click to view more from Pulmonology Data Trends 2023.

References
  1. Global tuberculosis report 2022. World Health Organization. Published October 27, 2022. Accessed June 26, 2023. https://www.who.int/publications/i/item/9789240061729
  2. WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment, 2022 update. World Health Organization. Published December 15, 2022. Accessed June 26, 2023. https://www.who.int/publications/i/item/9789240063129
  3. Migliori GB, Tiberi S. Int J Tuberc Lung Dis. 2022 ;26(7):590-591. doi:10.5588/ijtld.22.0263.
  4. Lange C et al. Am J Respir Crit Care Med. 2022;205(10):1142-1144. doi:10.1164/rccm.202202-0393ED
  5. Esmail A et al. Am J Respir Crit Care Med. 2022;205(10):1214-1227. doi:10.1164/rccm.202107-1779OC
  6. WHO BPaLM Accelerator Platform: to support the call to action for implementation of the shorter and more effective treatment for all people suffering from drug-resistant TB. World Health Organization. Published May 9, 2023. Accessed June 26, 2023. https://www.who.int/news-room/events/detail/2023/05/09/default-calendar/who-bpalm-accelerator-platform–to-support-the-call-to-action-for-implementation-of-the-shorter-and-moreeffective-
  7. Trevisi L et al. Am J Respir Crit Care Med. 2023;207(11):1525-1532. doi:10.1164/rccm.202211-2125OC
  8. Domínguez J et al; TBnet and RESIST-TB networks. Lancet Infect Dis. 2023;23(4):e122-e137. doi:10.1016/S1473-3099(22)00875-1
  9. WHO operational handbook on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection, 2021 update. World Health Organization. Published July 7, 2021. Accessed June 26, 2023. https://www.who.int/publications/i/item/9789240030589treatment-for-all-people-suffering-from-drug-resistant-tb
Author and Disclosure Information

Patricio Escalante, MD, MSc, FCCP
Professor of Medicine and Consultant
Division of Pulmonary, Critical Care Medicine, and Sleep Medicine
Mayo Clinic
Rochester, MN

Paige K. Marty, MD
Fellow
Division of Pulmonary and Critical Care Medicine
Mayo Clinic
Rochester, MN

Publications
MDedge Internal Medicine
CHEST Physician
Topics
Pulmonology
Author(s)
Patricio Escalante, MD, MSc, FCCP, and Paige K. Marty, MD
Author(s)
Patricio Escalante, MD, MSc, FCCP, and Paige K. Marty, MD
Author and Disclosure Information

Patricio Escalante, MD, MSc, FCCP
Professor of Medicine and Consultant
Division of Pulmonary, Critical Care Medicine, and Sleep Medicine
Mayo Clinic
Rochester, MN

Paige K. Marty, MD
Fellow
Division of Pulmonary and Critical Care Medicine
Mayo Clinic
Rochester, MN

Author and Disclosure Information

Patricio Escalante, MD, MSc, FCCP
Professor of Medicine and Consultant
Division of Pulmonary, Critical Care Medicine, and Sleep Medicine
Mayo Clinic
Rochester, MN

Paige K. Marty, MD
Fellow
Division of Pulmonary and Critical Care Medicine
Mayo Clinic
Rochester, MN

Click to view more from Pulmonology Data Trends 2023.

Click to view more from Pulmonology Data Trends 2023.

References
  1. Global tuberculosis report 2022. World Health Organization. Published October 27, 2022. Accessed June 26, 2023. https://www.who.int/publications/i/item/9789240061729
  2. WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment, 2022 update. World Health Organization. Published December 15, 2022. Accessed June 26, 2023. https://www.who.int/publications/i/item/9789240063129
  3. Migliori GB, Tiberi S. Int J Tuberc Lung Dis. 2022 ;26(7):590-591. doi:10.5588/ijtld.22.0263.
  4. Lange C et al. Am J Respir Crit Care Med. 2022;205(10):1142-1144. doi:10.1164/rccm.202202-0393ED
  5. Esmail A et al. Am J Respir Crit Care Med. 2022;205(10):1214-1227. doi:10.1164/rccm.202107-1779OC
  6. WHO BPaLM Accelerator Platform: to support the call to action for implementation of the shorter and more effective treatment for all people suffering from drug-resistant TB. World Health Organization. Published May 9, 2023. Accessed June 26, 2023. https://www.who.int/news-room/events/detail/2023/05/09/default-calendar/who-bpalm-accelerator-platform–to-support-the-call-to-action-for-implementation-of-the-shorter-and-moreeffective-
  7. Trevisi L et al. Am J Respir Crit Care Med. 2023;207(11):1525-1532. doi:10.1164/rccm.202211-2125OC
  8. Domínguez J et al; TBnet and RESIST-TB networks. Lancet Infect Dis. 2023;23(4):e122-e137. doi:10.1016/S1473-3099(22)00875-1
  9. WHO operational handbook on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection, 2021 update. World Health Organization. Published July 7, 2021. Accessed June 26, 2023. https://www.who.int/publications/i/item/9789240030589treatment-for-all-people-suffering-from-drug-resistant-tb
References
  1. Global tuberculosis report 2022. World Health Organization. Published October 27, 2022. Accessed June 26, 2023. https://www.who.int/publications/i/item/9789240061729
  2. WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment, 2022 update. World Health Organization. Published December 15, 2022. Accessed June 26, 2023. https://www.who.int/publications/i/item/9789240063129
  3. Migliori GB, Tiberi S. Int J Tuberc Lung Dis. 2022 ;26(7):590-591. doi:10.5588/ijtld.22.0263.
  4. Lange C et al. Am J Respir Crit Care Med. 2022;205(10):1142-1144. doi:10.1164/rccm.202202-0393ED
  5. Esmail A et al. Am J Respir Crit Care Med. 2022;205(10):1214-1227. doi:10.1164/rccm.202107-1779OC
  6. WHO BPaLM Accelerator Platform: to support the call to action for implementation of the shorter and more effective treatment for all people suffering from drug-resistant TB. World Health Organization. Published May 9, 2023. Accessed June 26, 2023. https://www.who.int/news-room/events/detail/2023/05/09/default-calendar/who-bpalm-accelerator-platform–to-support-the-call-to-action-for-implementation-of-the-shorter-and-moreeffective-
  7. Trevisi L et al. Am J Respir Crit Care Med. 2023;207(11):1525-1532. doi:10.1164/rccm.202211-2125OC
  8. Domínguez J et al; TBnet and RESIST-TB networks. Lancet Infect Dis. 2023;23(4):e122-e137. doi:10.1016/S1473-3099(22)00875-1
  9. WHO operational handbook on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection, 2021 update. World Health Organization. Published July 7, 2021. Accessed June 26, 2023. https://www.who.int/publications/i/item/9789240030589treatment-for-all-people-suffering-from-drug-resistant-tb
Publications
MDedge Internal Medicine
CHEST Physician
Publications
MDedge Internal Medicine
CHEST Physician
Topics
Pulmonology
Article Type
Article
Display Headline
Tuberculosis Management: Returning to Pre-Pandemic Priorities
Display Headline
Tuberculosis Management: Returning to Pre-Pandemic Priorities
Disallow All Ads
Content Gating
Open Access (article Unlocked/Open Access)
Alternative CME
Disqus Comments
Default
Eyebrow Default
Slideshow
Gate On Date
Sat, 09/30/2023 - 09:15
Un-Gate On Date
Sat, 09/30/2023 - 09:15
Use ProPublica
CFC Schedule Remove Status
Sat, 09/30/2023 - 09:15
Hide sidebar & use full width
Do not render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Article Slideshow Optional Introduction

Slideshow below.

Although we are officially living in a “post-pandemic” world, some long-term global impacts of COVID-19 are still being addressed. We remain off track on global tuberculosis (TB) milestone targets due to halted progress over the last 3 years, with more people going undiagnosed and untreated for TB compared with pre-pandemic years.1 Drug-resistant TB (DR-TB) and multidrug-resistant TB (MDR-TB) continue to represent a major burden, and global spending on TB efforts remains significantly lower than what is needed to reach goals set forth by WHO.1

Despite these challenges, there are also some exciting updates. We now know that TB treatment success rates remained steady during the pandemic (86%), and strong efforts have been made to address DR-TB and MDR-TB via improved treatment options with highly effective, all-oral, shortened treatment regimens, as well as new and promising testing modalities.1-3

Slide
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Slide Media
Subscribe to Patricio Escalante, MD, MSc, FCCP, and Paige K. Marty, MD